Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Net Cash Flow (2021 - 2025)

Amylyx Pharmaceuticals has reported Net Cash Flow over the past 5 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $1.4 million for Q4 2025, down 77.69% from a year ago — trailing twelve months through Dec 2025 was $147.7 million (up 261.19% YoY), and the annual figure for FY2025 was $147.7 million, up 261.19%.
  • Net Cash Flow for Q4 2025 was $1.4 million at Amylyx Pharmaceuticals, down from $166.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for AMLX hit a ceiling of $166.5 million in Q3 2025 and a floor of -$112.4 million in Q3 2023.
  • Median Net Cash Flow over the past 5 years was $909000.0 (2024), compared with a mean of $10.7 million.
  • Peak annual rise in Net Cash Flow hit 6325.65% in 2025, while the deepest fall reached 3965.73% in 2025.
  • Amylyx Pharmaceuticals' Net Cash Flow stood at -$26.5 million in 2021, then plummeted by 72.54% to -$45.7 million in 2022, then soared by 175.92% to $34.7 million in 2023, then crashed by 82.48% to $6.1 million in 2024, then crashed by 77.69% to $1.4 million in 2025.
  • The last three reported values for Net Cash Flow were $1.4 million (Q4 2025), $166.5 million (Q3 2025), and -$2.3 million (Q2 2025) per Business Quant data.